Acromegaly is a syndrome of chronic growth hormone excess, almost always caused by a benign pituitary adenoma. Excess GH antagonizes insulin, so roughly 30 to 50 percent of patients develop diabetes or impaired glucose tolerance. Treatment of the underlying tumor frequently improves glucose control.
What Acromegaly Is
Acromegaly is a rare disorder with an estimated prevalence of 40 to 130 cases per million. Onset is insidious; diagnosis is often delayed by 5 to 10 years from the first symptoms. The same hormonal excess in childhood (before growth plate fusion) causes gigantism with very tall stature.
- Cause: GH-secreting pituitary adenoma (greater than 95 percent)
- Rare causes: ectopic GHRH from neuroendocrine tumors, ectopic GH from non-pituitary tumors
- Excess GH drives liver to produce insulin-like growth factor 1 (IGF-1)
- Most clinical features mediated by IGF-1; metabolic effects partly mediated by GH directly
Why Acromegaly Causes Diabetes
GH is a counterregulatory hormone — its physiologic role includes raising blood glucose. Chronic excess produces:
- Hepatic insulin resistance with increased gluconeogenesis
- Reduced glucose uptake by skeletal muscle
- Increased lipolysis with elevated free fatty acids
- Beta-cell stress and eventual failure in susceptible individuals
Approximately 30 to 50 percent of acromegaly patients have overt diabetes or impaired glucose tolerance at diagnosis. Diabetes is associated with older age, longer disease duration, higher GH/IGF-1 levels, family history of type 2 diabetes, and obesity. See our pillar on complications and related conditions for broader context on diabetes complications.
Clinical Features
- Coarsening of facial features over years
- Frontal bossing, brow ridge prominence
- Prognathism (jaw protrusion) and widening of teeth gaps
- Enlargement of hands and feet — ring resizing, increasing shoe size
- Deepened voice from laryngeal soft tissue growth
- Macroglossia and obstructive sleep apnea
- Excessive sweating and oily skin
- Skin tags
- Headaches
- Carpal tunnel syndrome
- Arthralgias and large-joint osteoarthritis
- Hypertension
- Cardiomyopathy with diastolic dysfunction
- Visual field defects from optic chiasm compression in large adenomas
- Menstrual disturbances or galactorrhea (if co-secreted prolactin)
Comorbidities
| System | Common Issues |
|---|---|
| Cardiovascular | Hypertension, cardiomyopathy, heart failure, arrhythmias |
| Metabolic | Diabetes, dyslipidemia, insulin resistance |
| Respiratory | Obstructive sleep apnea, upper-airway soft-tissue enlargement |
| Musculoskeletal | Arthropathy, vertebral fractures, carpal tunnel |
| Oncologic | Increased colon polyp risk; thyroid nodules |
| Endocrine | Hypopituitarism, hyperprolactinemia |
How Clinicians Diagnose Acromegaly
- Serum IGF-1 against age-matched reference ranges (screening test)
- Oral glucose tolerance test with GH measurement — GH that fails to suppress below approximately 1 ng/mL is confirmatory
- MRI of the pituitary with and without contrast — to localize and size the adenoma
- Visual field testing if the adenoma abuts the optic chiasm
- Anterior pituitary function panel — prolactin, TSH, free T4, ACTH, cortisol, LH, FSH, testosterone or estradiol
- Echocardiogram for cardiac assessment
- Sleep study for OSA
- Colonoscopy at diagnosis given increased polyp risk
Glucose Workup in Acromegaly
- Fasting glucose and A1C at diagnosis — see A1C levels
- Oral glucose tolerance test, primarily for GH suppression but also reveals glucose status
- Lipid panel
- Liver enzymes
- Repeat assessment after each treatment phase
Treatment of Acromegaly
Treatment goals are normalization of IGF-1, reduction of GH levels, control of tumor mass, relief of symptoms, and management of comorbidities. Approaches include:
- Transsphenoidal surgery — first-line for most patients; performed by an experienced pituitary neurosurgeon
- Somatostatin receptor ligands — octreotide LAR, lanreotide depot, pasireotide LAR (second-generation)
- GH receptor antagonist — pegvisomant (subcutaneous daily)
- Dopamine agonists — cabergoline, especially for mild disease or co-secreted prolactin
- Radiotherapy — stereotactic radiosurgery or conventional fractionated radiotherapy for residual or recurrent disease
- Combination therapy when monotherapy is inadequate
Diabetes Management Considerations
- Metformin is generally appropriate first-line — see treatment
- GLP-1 receptor agonists may help with weight, glycemia, and cardiovascular risk
- SGLT2 inhibitors offer cardiorenal protection
- Insulin may be needed transiently with pasireotide or during high disease activity
- Monitor for medication interactions and altered absorption
- Lifestyle measures — see diet and nutrition — remain foundational
What Happens to the Diabetes After Treatment
Glucose control typically improves substantially with biochemical control of acromegaly. Studies have shown reductions in fasting glucose, A1C, and insulin requirements after successful surgery or with effective medical therapy. Patients on pasireotide are a notable exception — pasireotide-induced hyperglycemia is common and often requires intensification of glucose-lowering therapy. Pegvisomant generally improves insulin sensitivity.
Differential Diagnosis
- Familial tall stature or sporadic pseudo-acromegaloid features
- Pachydermoperiostosis
- Severe obesity or chronic kidney disease (mild IGF-1 elevations)
- Pregnancy (placental GH variant)
- Estrogen therapy (lowers IGF-1)
- Cushing syndrome (overlap of facial changes and diabetes)
Prognosis
Acromegaly is associated with increased cardiovascular and respiratory mortality, but with modern treatment that normalizes IGF-1, mortality approaches that of the general population. Cardiometabolic risk reduction — including blood pressure control, lipid management, glucose control, sleep apnea treatment, and weight management — is central to long-term outcomes.
When to See a Doctor
- Persistent increase in ring or shoe size
- New facial coarsening recognized in old photographs
- New deep voice, increased sweating, sleep apnea symptoms
- New diabetes plus features suggestive of pituitary dysfunction
- New visual disturbances or persistent headaches
- Suspected family member with acromegaly or familial pituitary syndromes (FIPA, MEN1, Carney complex)
The Bottom Line
Acromegaly is a rare but important secondary cause of diabetes — chronic growth hormone excess antagonizes insulin and produces diabetes or impaired glucose tolerance in roughly a third to half of patients. Recognition often takes years because changes are slow; new facial coarsening, enlarging hands and feet, and unexplained diabetes are clues. Surgical removal of the pituitary adenoma is first-line, with medical therapy and radiotherapy as backup. Glucose control typically improves with biochemical remission. Talk to your doctor and consider endocrinology referral if you have features suggestive of acromegaly.
